Recent events force the question: What is the best plan to reduce the burden of infectious disease globally through vaccination and prevention? Q2 Solutions has long been at the forefront, aiding in the development of new vaccines faster and with better methodologies in partnership with premier organizations focused on this task. We continue to commit to prioritizing a swift response to global threats to public health through innovation, collaboration, and action.
Our longstanding expertise and track record in infectious disease crosses the spectrum of assay development and testing.
At Q2 Solutions, we approach each vaccine program with disciplined agility: scientific excellence and full transparency with the flexibility, ingenuity, and capacity for the quick decision-making needed. Our expertise is built on a foundation of 20 years of experience in vaccine efficacy and safety evaluation as a partner to industry leading vaccine manufacturers worldwide. Cutting-edge technology platforms and state-of-the-art laboratories enable us to best develop, qualify, and validate single and multiplex immunological assays and sample testing to support vaccine development.
Q2 Solutions has seven integrated platforms that help you progress from vaccine development through clinical evaluation. Our main focus is on the evaluation of the efficacy of the vaccine —be it in the developmental stages or in clinical immunological responses. Critical reagents and well-established assays are indispensable to the efficient assessment of vaccine candidates. We take pride in our ability to develop innovative and critical reagents in-house. This capacity allows us to scale rapidly and helps control batch-to-batch variations of assay materials— crucial factors in maintaining operational excellence, high quality data, and world class science for our clients.
Challenges to develop suitable assays and tests increase when vaccine development is accelerated in response to emerging infectious disease threats. At Q2 Solutions, we develop custom assays relevant to the disease state which is further adapted as the disease evolves. This progressive approach provides an early prediction of how the vaccine translates later phase clinical trials. A successful vaccine project requires not only an experienced partner who understands the complexity presented in the research, but one that also has the capability to scale operations.
Our end-to-end translational support for your vaccine and immunotherapy programs ranges from lead compound selection to post-market registration. In addition, our innovative and fit-for-purpose working models are ideal for evaluating the efficacy and immunogenicity of your vaccine candidates needed for regulatory approvals.
Our functional antibody assays for bacteria include complex assays such as:
The molecular biology platform performs PCR-based assays to support vaccine studies. Our qPCR and RT-qPCR assays are used for quantification of the vaccine candidate particles (genome copies) in the samples to support viral shedding studies.
Vaccine development and evaluations require highly sensitive and quantitative methods that can measure a broad range of molecules such as cytokines, antigenic and cellular markers. Our cellular assays include the following:
ELISpot – Enzyme-linked immunosorbent spot (ELISpot) is a highly flexible and versatile assay that can be adapted to multiple readout formats. ELISpot assays are quantitative and measure key cellular functions of immune system cells. They are useful for assessing both adaptive (humoral) and innate (cell-mediated) immune responses to a vaccine.
In order to identify mediators of short- and/or long-term immunity, a robust method of identification, sorting, and characterization is needed.